New application of csf2 gene and its expression product

A technology of gene and gene suppression, applied in the application field of CSF2 gene and its expression products in the diagnosis and treatment of intracranial aneurysms, can solve the problems of interfering with CSF2 gene, no research revealing the relationship between intracranial aneurysms, and affecting the activity of EPCs, etc., to achieve Fast and accurate quantification, good application prospects, and strong selectivity

Active Publication Date: 2020-02-07
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The inventors analyzed 5 cases of intracranial aneurysm wall tissue and 3 cases based on high-throughput sequencing, and selected a significantly high-expressed candidate gene CSF2 among differentially expressed genes. Proliferation and differentiation, but no research has revealed its relationship with intracranial aneurysms. The inventors conducted RT-PCR verification and cell verification, and confirmed that CSF2 is highly expressed in the intracranial aneurysm group, and interference with CSF2 gene expression will affect EPCs Activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of csf2 gene and its expression product
  • New application of csf2 gene and its expression product
  • New application of csf2 gene and its expression product

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] The collection of embodiment 1 case

[0036] All tissue samples were from patients with intracranial aneurysms diagnosed by DSA from October 2012 to May 2014, and underwent microsurgical craniotomy. The aneurysm tissue samples were the aneurysm wall tissue removed during microsurgery, and the control normal cerebrovascular tissue samples were the superficial temporal artery (STA) and / or middle meningeal artery (MMA) of brain tumor craniotomy patients at the same period. In order to minimize the differences between samples, all aneurysm tissue samples were selected from saccular aneurysms. The obtained tissue samples were immediately placed in a liquid nitrogen tank.

Embodiment 2

[0037] Example 2 High-throughput sequencing and analysis

[0038] After the RNA is extracted, agarose gel electrophoresis is performed. From the electrophoresis results, it can be preliminarily judged whether the quality of the extracted RNA sample is qualified or not, and whether it can be used for further transcriptome sequencing. Then, the extraction of RNA samples was detected by NanoDrop1000 spectrophotometer, and the sample requirements for RNA-seq sequencing: OD260 / OD280 was 1.8-2.2. The qualified samples were sent to the sequencing company for sequencing. The sequencing platform was HiSeq 2500 high-throughput sequencing platform of Illumina Company for deep sequencing of high-throughput transcriptome. The results of data analysis provided by the sequencing company were combined with the literature to screen the differentially expressed gene CSF2.

Embodiment 4

[0039] Example 4 CSF2 gene expression of intracranial aneurysm patient group and control group

[0040] 1. Materials

[0041] Aneurysm wall tissues from 23 cases of intracranial aneurysm patients and 11 cases of normal control cerebrovascular samples were selected and grouped and numbered. See Example 1 for sample collection criteria.

[0042] 2. Method

[0043] 2.1 Extraction of RNA

[0044] 1) Put small pieces of aneurysm (normal control blood vessel) tissue in a petri dish, add 1ml Trizol, cut it into pieces with ophthalmic scissors, and transfer to a homogenizer for homogenization;

[0045] 2) After the homogenization is completed, take out the homogenate and place it in an EP tube, set the volume to 1ml, and store it at -70°C;

[0046] 3) Place at 15-30°C for 5 minutes, add 200 μl chloroform, shake vigorously for 15 sec, and place at 15-30°C for 10 minutes;

[0047] 4) 2-8°C, centrifuge at less than 12000g / min for 10min, discard the supernatant, add 1ml of 75% ethano...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
pore sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to a CSF2 gene and new application of an expression product of the CSF2 gene, in particular to the CSF2 gene and the application of the expression product of the CSF2 gene to treatment of intracranial aneurysm. Candidate CSF2 genes are selected by the inventor on the basis of high-throughput sequencing analysis, RT-PCR verification and cell verification are conducted, and the result shows that SCF2mRAN is highly expressed in an intracranial aneurysm group and activity of EPCs can be influenced when the CSF2 genes are disturbed. The invention provides a new potential treatment target spot for intracranial aneurysm, and important clinical application value is achieved.

Description

technical field [0001] The present invention relates to tumor markers, in particular to the new application of CSF2 gene and its expression product, and more specifically to the application of CSF2 gene and its expression product in diagnosis and treatment of intracranial aneurysm. Background technique [0002] Intracranial aneurysm (IA) is a cerebral hemangioma-like protrusion produced by pathological and limited expansion of the arterial wall, and its rupture is the first cause of spontaneous subarachnoid hemorrhage in humans (about 79%-89% ), accounting for 25% of intracranial hemorrhage, its fatality rate and disability rate are extremely high, seriously affecting people's health and life. With the development of imaging technology and the improvement of people's health awareness, the detection rate of unruptured aneurysms has also increased. Intracranial aneurysms have become one of the common and frequently occurring cerebrovascular diseases. After more than 100 years...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886C12N15/11C12N15/113G01N33/68G01N33/574A61K48/00A61K38/00A61P35/00
CPCA61K38/00A61K48/00C12N15/113C12Q1/686G01N33/57407G01N33/68C12Q2563/107C12Q2545/114C12Q2531/113
Inventor 杨承刚宋宏涛
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap